Last $1.57 USD
Change Today +0.025 / 1.62%
Volume 12.5K
PDII On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

pdi inc (PDII) Snapshot

Open
$1.54
Previous Close
$1.54
Day High
$1.59
Day Low
$1.54
52 Week High
01/31/14 - $6.00
52 Week Low
01/16/15 - $1.30
Market Cap
24.0M
Average Volume 10 Days
46.2K
EPS TTM
$-0.82
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PDI INC (PDII)

pdi inc (PDII) Related Bloomberg News

View More Bloomberg News

pdi inc (PDII) Related Businessweek News

No Related Businessweek News Found

pdi inc (PDII) Details

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, and healthcare companies in the United States. The company’s services offer customers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It operates in three segments: Sales Services, Marketing Services, and Product Commercialization Services. The Sales Services segment focuses primarily on product detailing, which includes a sales representative meeting face-to-face with targeted physicians and other healthcare decision makers to provide a technical review of the product being promoted and deliver marketing materials, including samples. It also offers a portfolio of sales services consisting of talent acquisition services, short-term teams, and vacancy coverage services. The Marketing Services segment is involved in the creation, design, and implementation of interactive digital communications programs to the healthcare community through the Internet, multimedia, tablet PCs, mobile devices, and dimensional direct mails, as well as DIAGRAM, a proprietary software to deliver digital selling solutions through interactive communications exchanges that accommodate the schedules of healthcare providers. This segment is also engaged in the creation of teledetailing programs executed through tele-representatives. The Product Commercialization Services segment provides product commercialization solutions, including product distribution, product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management to pharmaceutical, biotechnology, medical device, and diagnostics clients. PDI, Inc. has a strategic collaboration agreement with Transgenomic, Inc. The company was founded in 1987 and is headquartered in Parsippany, New Jersey.

706 Employees
Last Reported Date: 03/6/14
Founded in 1987

pdi inc (PDII) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
President of Sales Services
Total Annual Compensation: $488.5K
Compensation as of Fiscal Year 2013.

pdi inc (PDII) Key Developments

PDI Inc. Re-Affirms Earnings Guidance for the Year 2014

PDI Inc. re-affirmed earnings guidance For the year 2014. For the year, the company expects an operating loss of $15 million to $17 million on a GAAP-basis, with revenues of $121 million to $123 million.

SWK Funding LLC Enters into Credit Agreement with PDI, Inc

On October 31, 2014, SWK Funding LLC entered into a credit agreement among pursuant to which the company provided to PDI, Inc. a term loan in the principal amount of $20,000,000. The loan matures on October 31, 2020. The loan bears interest at the greater of three month LIBOR and 1.0%, plus a margin of 12.5%, payable in cash quarterly in arrears, beginning on February 17, 2015. The interest rate will be increased by 3.0% in the event of a default under the credit agreement. Interest and principal under the loan will be paid by a tiered revenue interest that is charged on quarterly net sales and royalties of the borrower applied in the following priority first, to the payment of all accrued but unpaid interest until paid in full; second to the payment of all principal of the loans. Beginning in January 2017, the Borrower will be required to make principal payments on the loan. Additionally, beginning in January 2017 and ending on October 31, 2020, subject to a $250,000 per quarter cap, the company will be entitled to receive quarterly revenue-based payments from the Borrower equal to 1.25% of revenue derived from net sales of molecular diagnostics products.

PDI, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

PDI, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's revenue, net was $29,245,000 compared to $34,260,000 a year ago. Operating loss was $4,223,000 compared to $2,052,000 a year ago. The 2014 operating loss was primarily the result of the expected lower revenue and margins as well as the company's investment in strategic initiatives. Loss from continuing operations before income tax was $4,243,000 compared to $2,049,000 a year ago. Loss from continuing operations was $4,307,000 compared to $2,113,000 a year ago. Net loss was $4,336,000 compared to $2,141,000 a year ago. Net loss per basic and diluted share of common stock was $0.29 compared to $0.15 a year ago. Adjusted LBITDA was $3,326,000 compared to $1,261,000 a year ago. For the nine months, the company's revenue, net was $93,601,000 compared to $114,428,000 a year ago. Operating loss was $8,243,000 compared to $646,000 a year ago. Loss from continuing operations before income tax was $8,293,000 compared to $676,000 a year ago. Loss from continuing operations was $8,487,000 compared to $868,000 a year ago. Net loss was $8,605,000 compared to $899,000 a year ago. Net loss per basic and diluted share of common stock was $0.58 compared to $0.06 a year ago. Adjusted LBITDA was $5,151,000 compared to adjusted EBITDA of $1,795,000 a year ago. Net cash used in operations was $7,966,000 compared to net cash provided by operations of $237,000 a year ago. The company anticipates revenue in core business to be in the range of $120 to $122 million. The company expects an operating loss in the range of $7 to $8 million and adjusted LBITDA of approximately $2 to $3 million in the core business for the full year 2014. Incorporating RedPath announcement within Interpace Diagnostics subsidiary, the company expects total revenue of approximately $121 to $123 million and adjusted LBITDA in the range of $12 to $13 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDII:US $1.57 USD +0.025

PDII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDII.
View Industry Companies
 

Industry Analysis

PDII

Industry Average

Valuation PDII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDI INC, please visit www.pdi-inc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.